Table 1.
Univariate and Multivariate Analyses for Disease-free Survival of Nuclear HIF-1α (1) and Clinicopathological Characteristics in ER-positive Cohort 1, Luminal A Tumors (n=175).
| Clinicopathological Characteristics | Luminal A Disease | |||
|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age (≤50/>50years) | 2.07 (1.17–3.65) | 0.013* | 1.48 (0.77–2.82) | 0.240 |
| Tumor size (≤2/2.1–5/>5 cm) | 1.73 (1.26–2.38) | 0.001* | 1.87 (1.24–2.81) | 0.003* |
| Grade (I/II/III) | 1.21 (0.89–1.66) | 0.229 | — | — |
| Involved lymph node (negative/positive) | 2.09 (1.38–3.19) | 0.001* | 1.75 (1.04–2.95) | 0.037* |
| PR status (negative/positive) | 0.95 (0.61–1.48) | 0.810 | — | — |
| Lymphatic vessel invasion (no/yes) | 1.46 (0.82–2.61) | 0.199 | — | — |
| Blood vessel invasion (no/yes) | 1.50 (0.68–3.34) | 0.315 | — | — |
| Tumor necrosis (low/high) | 1.03 (0.66–1.61) | 0.885 | — | — |
| Klintrup–Mäkinen grade (low/high) | 0.64 (0.45–0.91) | 0.013* | 0.64 (0.41–1.01) | 0.055 |
| CD68+ (low/moderate/high) | 0.94 (0.63–1.39) | 0.743 | — | — |
| CD8+ (low/moderate/high) | 1.07 (0.73–1.58) | 0.713 | — | — |
| CD138+ (low/moderate/high) | 1.04 (0.74–1.46) | 0.820 | — | — |
| Tumor stroma percentage (low/high) | 2.06 (1.35–3.13) | 0.001* | 2.18 (1.32–3.61) | 0.002* |
| Tumor budding (low/high) | 1.39 (0.92–2.12) | 0.122 | — | — |
| Adjuvant endocrine therapy (no/yes/ATAC trial) | 1.43 (0.73–2.84) | 0.300 | — | — |
| Adjuvant chemotherapy (no/yes) | 0.92 (0.58–1.47) | 0.725 | — | — |
| Adjuvant radiotherapy (no/yes) | 0.68 (0.45–1.04) | 0.078 | — | — |
| Nuclear HIF-1α (1) (low/high) | 0.56 (0.32–0.98) | 0.038* | 0.53 (0.30–0.94) | 0.030* |
Abbreviations: HIF-1α (1), hypoxia-inducible factor-1α (1); ER, estrogen receptor; HR, hazard ratio; CI, confidence interval; PR, progesterone receptor; ATAC, Arimidex, Tamoxifen, Alone or in Combination.
*
Statistically significant p value <0.05.